334 related articles for article (PubMed ID: 27661115)
1. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
Voltan R; Rimondi E; Melloni E; Rigolin GM; Casciano F; Arcidiacono MV; Celeghini C; Cuneo A; Zauli G; Secchiero P
Oncotarget; 2016 Oct; 7(43):70623-70638. PubMed ID: 27661115
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
Zauli G; Voltan R; Bosco R; Melloni E; Marmiroli S; Rigolin GM; Cuneo A; Secchiero P
Clin Cancer Res; 2011 Feb; 17(4):762-70. PubMed ID: 21106726
[TBL] [Abstract][Full Text] [Related]
3. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
[TBL] [Abstract][Full Text] [Related]
4. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
5. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.
Agnoletto C; Melloni E; Casciano F; Rigolin GM; Rimondi E; Celeghini C; Brunelli L; Cuneo A; Secchiero P; Zauli G
Oncotarget; 2014 Jun; 5(12):4347-60. PubMed ID: 24962518
[TBL] [Abstract][Full Text] [Related]
6. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D
Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951
[TBL] [Abstract][Full Text] [Related]
7. Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.
Secchiero P; Melloni E; di Iasio MG; Tiribelli M; Rimondi E; Corallini F; Gattei V; Zauli G
Blood; 2009 Apr; 113(18):4300-8. PubMed ID: 19190243
[TBL] [Abstract][Full Text] [Related]
8. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Hing ZA; Mantel R; Beckwith KA; Guinn D; Williams E; Smith LL; Williams K; Johnson AJ; Lehman AM; Byrd JC; Woyach JA; Lapalombella R
Blood; 2015 May; 125(20):3128-32. PubMed ID: 25838351
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
10. p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.
Lee HJ; Gallardo M; Ma H; Zhang X; Larsson CA; Mejia A; Hornbaker MJ; Qi Y; Su X; Pageon LR; Quintas-Cardama A; Post SM
Blood Cancer J; 2016 Jun; 6(6):e434. PubMed ID: 27284738
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts.
Voltan R; Secchiero P; Ruozi B; Forni F; Agostinis C; Caruso L; Vandelli MA; Zauli G
Clin Cancer Res; 2013 Jul; 19(14):3871-80. PubMed ID: 23719263
[TBL] [Abstract][Full Text] [Related]
12. Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity.
Zauli G; di Iasio MG; Secchiero P; Dal Bo M; Marconi D; Bomben R; Del Poeta G; Gattei V
Curr Cancer Drug Targets; 2009 Jun; 9(4):510-8. PubMed ID: 19519319
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53(wild-type) JVM-2 but not towards p53(mutated) BJAB leukemic cells.
Voltan R; Secchiero P; Ruozi B; Caruso L; Forni F; Palomba M; Zauli G; Vandelli MA
Curr Med Chem; 2013; 20(21):2712-22. PubMed ID: 23627936
[TBL] [Abstract][Full Text] [Related]
14. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
Guo Y; Li Y; Wang FF; Xiang B; Huang XO; Ma HB; Gong YP
Int J Biochem Cell Biol; 2019 Jan; 106():8-20. PubMed ID: 30389549
[TBL] [Abstract][Full Text] [Related]
15. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
Boudny M; Zemanova J; Khirsariya P; Borsky M; Verner J; Cerna J; Oltova A; Seda V; Mraz M; Jaros J; Jaskova Z; Spunarova M; Brychtova Y; Soucek K; Drapela S; Kasparkova M; Mayer J; Paruch K; Trbusek M
Haematologica; 2019 Dec; 104(12):2443-2455. PubMed ID: 30975914
[TBL] [Abstract][Full Text] [Related]
16. Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors.
Rimondi E; Melloni E; Romani A; Tisato V; Casciano F; Rigolin GM; Milani D; Celeghini C; Zauli G; Secchiero P; Voltan R
Curr Oncol; 2021 Jul; 28(4):2439-2451. PubMed ID: 34287267
[TBL] [Abstract][Full Text] [Related]
17. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.
Amin NA; Balasubramanian S; Saiya-Cork K; Shedden K; Hu N; Malek SN
Clin Cancer Res; 2017 Feb; 23(4):1049-1059. PubMed ID: 27535981
[No Abstract] [Full Text] [Related]
18. The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
Secchiero P; Voltan R; di Iasio MG; Melloni E; Tiribelli M; Zauli G
Clin Cancer Res; 2010 Mar; 16(6):1824-33. PubMed ID: 20215548
[TBL] [Abstract][Full Text] [Related]
19. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
20. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
